<!DOCTYPE html><html lang="en"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width,initial-scale=1"><title>Adrenergic_Cholinergic V - BHOLE</title><meta name="description" content="IntroCholinomimeticsDIRECT Cholinomimetic: Agonists on muscarinic and nicotinic receptorsMuscarinic AgonistNicotinic Agonist:Indirect Cholinomimetic: AChE inhibitorsReversible and thereapeuticOrganophosphates - Irreversible, toxicTOXICITY MANIFESTATION AFTER ORGANOPHOSPHATES (OPs) EXPOSURE:CholinolyticsIndirectDirectMuscarinic Anatgonists:Nicotinic Antagonists: NMJ blocksTextbook NotesIntroAceytlchole binds on both Nicotinic and Muscarinic receptorsOn nictotinic it has an ionotropric effect, allowing passage of ions.On&hellip;"><meta name="generator" content="Publii Open-Source CMS for Static Site"><link rel="canonical" href="https://BGASM.github.io/medNotes/adrenergic_cholinergic-v.html"><link rel="alternate" type="application/atom+xml" href="https://BGASM.github.io/medNotes/feed.xml"><link rel="alternate" type="application/json" href="https://BGASM.github.io/medNotes/feed.json"><meta property="og:title" content="Adrenergic_Cholinergic V"><meta property="og:site_name" content="BHOLE"><meta property="og:description" content="IntroCholinomimeticsDIRECT Cholinomimetic: Agonists on muscarinic and nicotinic receptorsMuscarinic AgonistNicotinic Agonist:Indirect Cholinomimetic: AChE inhibitorsReversible and thereapeuticOrganophosphates - Irreversible, toxicTOXICITY MANIFESTATION AFTER ORGANOPHOSPHATES (OPs) EXPOSURE:CholinolyticsIndirectDirectMuscarinic Anatgonists:Nicotinic Antagonists: NMJ blocksTextbook NotesIntroAceytlchole binds on both Nicotinic and Muscarinic receptorsOn nictotinic it has an ionotropric effect, allowing passage of ions.On&hellip;"><meta property="og:url" content="https://BGASM.github.io/medNotes/adrenergic_cholinergic-v.html"><meta property="og:type" content="article"><link rel="preconnect" href="https://fonts.gstatic.com/" crossorigin><link href="https://fonts.googleapis.com/css?family=Open+Sans:400,700|Roboto:400,700&amp;subset=latin-ext&amp;display=swap" rel="stylesheet"><style>:root{--body-font:'Open Sans',sans-serif;--heading-font:'Roboto',sans-serif;--logo-font:'Roboto',sans-serif;--menu-font:'Roboto',sans-serif}</style><link rel="stylesheet" href="https://BGASM.github.io/medNotes/assets/css/style.css?v=d2564d8d5f32cbb5488692bb93d80cc5"><script type="application/ld+json">{"@context":"http://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://BGASM.github.io/medNotes/adrenergic_cholinergic-v.html"},"headline":"Adrenergic_Cholinergic V","datePublished":"2020-12-06T17:03","dateModified":"2020-12-06T17:04","description":"IntroCholinomimeticsDIRECT Cholinomimetic: Agonists on muscarinic and nicotinic receptorsMuscarinic AgonistNicotinic Agonist:Indirect Cholinomimetic: AChE inhibitorsReversible and thereapeuticOrganophosphates - Irreversible, toxicTOXICITY MANIFESTATION AFTER ORGANOPHOSPHATES (OPs) EXPOSURE:CholinolyticsIndirectDirectMuscarinic Anatgonists:Nicotinic Antagonists: NMJ blocksTextbook NotesIntroAceytlchole binds on both Nicotinic and Muscarinic receptorsOn nictotinic it has an ionotropric effect, allowing passage of ions.On&hellip;","author":{"@type":"Person","name":"William Slattery"},"publisher":{"@type":"Organization","name":"William Slattery"}}</script></head><body><div class="site-container"><header class="top" id="js-header"><a class="logo" href="https://BGASM.github.io/medNotes/">BHOLE</a><nav class="navbar js-navbar"><button class="navbar__toggle js-toggle" aria-label="Menu" aria-haspopup="true" aria-expanded="false"><span class="navbar__toggle-box"><span class="navbar__toggle-inner">Menu</span></span></button><ul class="navbar__menu"><li><a href="https://github.com/BGASM" target="_self">My Github</a></li><li class="active-parent has-submenu"><span class="is-separator" aria-haspopup="true">Fall 2020</span><ul class="navbar__submenu level-2" aria-hidden="true"><li class="active-parent has-submenu"><span class="is-separator" aria-haspopup="true">Pharmacology</span><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems.html" target="_self">Adrenergic and Cholinergic I</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems-ii.html" target="_self">Adrenergic and Cholinergic II</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-pharm-iii.html" target="_self">Adrenergic and Cholinergic III</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-inhibitors.html" target="_self">Adrenergic and Cholinergic IV</a></li><li class="active"><a href="https://BGASM.github.io/medNotes/adrenergic_cholinergic-v.html" target="_self">Adrenergic and Cholinergic V</a></li><li><a href="https://BGASM.github.io/medNotes/chemotherapy-i.html" target="_self">Chemotherapy I</a></li><li><a href="https://BGASM.github.io/medNotes/chemotherapy-ii.html" target="_self">Chemotherapy II</a></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">Pathophysiology</span><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/edema-congestion-and-hemostasis.html" target="_self">Edema Congestion and Hemostasis</a></li><li><a href="https://BGASM.github.io/medNotes/hemorrhage-thrombosis-and-embolism-2.html" target="_self">Hemorrhage Thrombosis and Embolism</a></li><li><a href="https://BGASM.github.io/medNotes/infarction-shock-and-dic.html" target="_self">Infarction Shock and DIC</a></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">MMG</span><ul class="navbar__submenu level-3" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/virology-i.html" target="_self">Virology I</a></li><li><a href="https://BGASM.github.io/medNotes/virology-ii.html" target="_self">Virology II</a></li><li><a href="https://BGASM.github.io/medNotes/virology-iii.html" target="_self">Virology III</a></li><li><a href="https://BGASM.github.io/medNotes/virology-v.html" target="_self">Virology V</a></li><li><a href="https://BGASM.github.io/medNotes/virology-vii.html" target="_self">Virology VII</a></li></ul></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">NMS</span><ul class="navbar__submenu level-2" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/02-principles-of-neurobiology.html" target="_self">NMS 02 - Principles of Neurobiology I</a></li><li><a href="https://BGASM.github.io/medNotes/nms03-principles-of-neurobiology-ii.html" target="_self">NMS 03 - Principles of Neurobiology II</a></li></ul></li><li><span class="is-separator">Peds</span></li><li><span class="is-separator">OPC</span></li></ul></nav></header><main><article class="post"><div class="hero"><figure class="hero__image hero__image--overlay"><img src="https://BGASM.github.io/medNotes/media/website/Jul24_GettyImages-582759294_neurons-scaled.jpg" srcset="https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-xs.jpg 300w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-sm.jpg 480w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-md.jpg 768w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-lg.jpg 1024w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-xl.jpg 1360w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-2xl.jpg 1600w" sizes="(max-width: 1600px) 100vw, 1600px" loading="eager" alt=""></figure><header class="hero__content"><div class="wrapper"><div class="post__meta"><time datetime="2020-12-06T17:03">December 6, 2020</time></div><h1>Adrenergic_Cholinergic V</h1><div class="post__meta post__meta--author"><a href="https://BGASM.github.io/medNotes/authors/william-slattery/" class="feed__author invert">William Slattery</a></div></div></header></div><div class="wrapper post__entry"><ul><li><a href="#intro">Intro</a><ul><li><a href="#"></a></li></ul></li><li><a href="#cholinomimetics">Cholinomimetics</a><ul><li><a href="#direct-cholinomimetic-agonists-on-muscarinic-and-nicotinic-receptors">DIRECT Cholinomimetic: Agonists on muscarinic and nicotinic receptors</a><ul><li><a href="#muscarinic-agonist">Muscarinic Agonist</a></li><li><a href="#nicotinic-agonist">Nicotinic Agonist:</a></li></ul></li><li><a href="#indirect-cholinomimetic-ache-inhibitors">Indirect Cholinomimetic: AChE inhibitors</a><ul><li><a href="#reversible-and-thereapeutic">Reversible and thereapeutic</a></li><li><a href="#organophosphates---irreversible-toxic">Organophosphates - Irreversible, toxic</a></li><li><a href="#toxicity-manifestation-after-organophosphates-ops-exposure">TOXICITY MANIFESTATION AFTER ORGANOPHOSPHATES (OPs) EXPOSURE:</a></li></ul></li></ul></li><li><a href="#cholinolytics">Cholinolytics</a><ul><li><a href="#indirect">Indirect</a></li><li><a href="#direct">Direct</a><ul><li><a href="#muscarinic-anatgonists">Muscarinic Anatgonists:</a></li><li><a href="#nicotinic-antagonists-nmj-blocks">Nicotinic Antagonists: NMJ blocks</a></li></ul></li></ul></li><li><a href="#textbook-notes">Textbook Notes</a><h2 id="intro">Intro</h2><h3></h3></li><li>Aceytlchole binds on both Nicotinic and Muscarinic receptors</li><li>On nictotinic it has an ionotropric effect, allowing passage of ions.</li><li>On muscarinic it binds to M receptors and has a metabotropic effect, which are all GPCRs</li><li>In PNS it is the parasympathetic system that uses Ach for post-ganglion signalling on muscarinic receptors</li><li>CNS<ul><li>Nictonic Effects: Reward, arousal, improve task performance</li><li>Muscarinic: Learning and memory Drugs acting on chilinergic systems in the PNS or CNS can act as either cholinomimetics, or cholinolytics.</li></ul></li></ul><h2 id="cholinomimetics">Cholinomimetics</h2><ul><li><p>Stimulate the cholinergic systems by enhancing the effects of either nicotinic or muscarinic receptors.</p></li><li><p>THey may also be indirectly stimulated by blocking AchE.</p></li><li><p>Directy agonists such as nicotine, Ach, carbachol, succinychole, or varenicline</p></li><li><p>Directly agonist such as pilocarpine and muscarine, ACh, Carbachol, Bethanechol, Methacholine, Cevimeline</p><h3 id="direct-cholinomimetic-agonists-on-muscarinic-and-nicotinic-receptors">DIRECT Cholinomimetic: Agonists on muscarinic and nicotinic receptors</h3><h4 id="muscarinic-agonist">Muscarinic Agonist</h4></li><li><p>Esters:</p><ul><li>Poorly absorveb and little CNS access because they are hydrophilic</li><li>They are hydrolyzed in the GI in the following priority:<ul><li>ACH &gt;&gt;&gt; METHacholine &gt;&gt;&gt; Bethanechol &gt;&gt;&gt; Carbachol</li></ul></li><li>ACh use is limited to some opthalmic procedures to cause miosis.</li><li>Carbachol has the longest duration<ul><li>Better choice drug for causing miosis</li><li>Constricts pupil and lowers IOP</li><li>Topical and intraoculare injections</li><li>AE: May cause asthma if it reaches PNS</li></ul></li><li>Bethanechol<ul><li>Selectivelty stimulates urinary and GI tract</li><li>Does not cause bradycardia</li><li><strong>Stimulate urinary retention</strong></li></ul></li><li>Methacholine<ul><li>Used for diagnostic only</li><li>Not used clinically</li><li>Asthma challenge test - bronchoprovocation test</li><li>Administer via inhlation</li><li>AE: Cardiac arrest</li></ul></li></ul></li><li><p>Alkaloids:</p><ul><li>Pilocarpine:<ul><li>Well absorbed</li><li>High affinity to mascarinic receptors: CNS and Periphery</li><li>Stimulates tears, sweating, saliva, pupil constriction, and contraction of ciliary muscle</li><li>TI: <strong>Glaucoma</strong> decrease IOP via topical or intraocular or dry mouth</li><li><strong>AE: Diaphoresis if it reaches systemic circulation</strong></li></ul></li></ul></li><li><p>Synthetics:</p><ul><li>CEVIMELINE (synthetic):<ul><li>Selectivity as M1 and M3 agonist.</li><li>Therapeutic uses: - <strong>Treat xerostomia (dry mouth)</strong>. It is a <strong>sialagogue</strong>.<h4 id="nicotinic-agonist">Nicotinic Agonist:</h4></li></ul></li></ul></li><li><p>Esters:</p><ul><li>ACh</li><li>Carbachol</li><li>Succinylcholine</li></ul></li><li><p>Alkaloids</p><ul><li>Nicotine:<ul><li>Only nicotinic stimulation: CNS and PNS</li><li>At a high dose it acts as a blocker. <strong>Desensitization</strong></li><li>Higher affinity for neuronal receptors than other tissue</li><li>CNS Stimulant: Increase respiratory rate, tremor, convulsions, vomiting</li><li>Parenteral Admin: Increase BP, nausea, diarrhea, bladder voiding<ul><li>TI: Nicotine Replacement therapy</li><li>AE: Increased salivation, upset stomach, bleeding gums, throat irritation</li><li>Symptoms of acute nicotine severe poisoning</li></ul></li><li>Nausea, salivatition, abdominal pain, vomiting, diarrhea, cold sweat, headache, dizziness, confusion, muscle weakness</li><li>Hypotension and rapid pulse</li><li>Labored breathing</li><li>Convulsions</li><li>Death from respiratory arrest</li></ul></li></ul></li><li><p>Synthetics:</p><ul><li>Varenicline<ul><li>Cross BBB</li><li>Partial agonist on nicotinic receptors in brain</li><li>TI: Smoking cessation</li><li>AE: Sleep disturbance and depression<h3 id="indirect-cholinomimetic-ache-inhibitors">Indirect Cholinomimetic: AChE inhibitors</h3></li></ul></li></ul></li><li><p>Increased amount of ACh to act in muscarinic and nicotinic receptors.</p></li><li><p>CNS: Enhance cholinergic function. High concentrations cause convulsions.</p></li><li><p><strong>Respiratory, GI, urinary tracts, and eye</strong>: Same as direct-acting cholinomimetics.</p></li><li><p><strong>Cardiovascular system</strong>: <strong>M2</strong> Inhibitory effect on heart predominates. Little effect on vasculature.</p><ul><li>Moderate doses – increase vascular resistance and BP.</li></ul></li><li><p>NMJ: Increase the strength of contraction, which may cause fasciculation and fibrillations and blockage.</p><h4 id="reversible-and-thereapeutic">Reversible and thereapeutic</h4></li><li><p>Neostigmine and Pyridostigmine: Reversible</p><ul><li>Low lipid solube so poort absorption</li><li>TI: Reverse effects of competititve NMJ blockers (<strong>non-depolarizing muscle releaxant</strong>)</li><li>Note, neostigmine also directly activates nicotinic receptors</li></ul></li><li><p>Physostigmine: Reversible</p><ul><li>Highly abosrbed by all routes</li><li>Access to CNS</li><li>TI: Glaucoma and reversing anticholinergic poisoning (like from atropine)</li></ul></li><li><p><strong>NEOSTIGMINE, PYRIDOSTIGMINE, and PHYSOSTIGMINE</strong>:</p><ul><li><strong>Myasthenia gravis (dec progression symptoms) Diagnosis of myasthenia gravis.</strong></li></ul></li><li><p>Donepezil, Galantamine, Rivastigmine: Reversible</p><ul><li>CNS action</li><li>TI: Alzeheimers Disease</li></ul></li></ul><h4 id="organophosphates---irreversible-toxic">Organophosphates - Irreversible, toxic</h4><ul><li>Parathion, Malathion (insecticides), Soman (gas), Sarin (liquid/evaporate as gas)<ul><li>Well absorbed from skin, lung, gut, conjunctiva</li><li>Lipid soluble: access to CNS.</li><li>Mechanism of Toxicity: Hydrolyzed by AChE, but the resulting phosphorylated enzyme.</li><li>form a very stable complex with the enzyme</li><li>bind to AChE irreversibly.</li><li>Require synthesis of the new enzyme to restore its function.</li><li>Malathion, parathion must be metabolized to be activated:</li></ul></li><li>Malathion: Moderately toxic (rapidly metabolized by other pathways to inactive forms in birds and mammals but not insects);</li><li>Parathion: Highly Toxic (not detoxified by vertebrates).<h4 id="toxicity-manifestation-after-organophosphates-ops-exposure">TOXICITY MANIFESTATION AFTER ORGANOPHOSPHATES (OPs) EXPOSURE:</h4></li><li>Acute (min- 24 h): effects include actions on CNS (anxiety, respiratory depression, convulsion)</li><li>Initial treatment will be atropine</li><li>Muscarinic symptoms: <strong>D U M B B EE L L S</strong>:<ul><li><strong>Diarrhea</strong></li><li>Urination</li><li><strong>Miosis</strong></li><li><strong>Bronchoconstriction</strong></li><li>Bradycardia</li><li>Excitation/Emesis</li><li>Lacrimation</li><li>Lethargy</li><li>Salivation</li><li><strong>Sweating</strong></li></ul></li><li>Nicitonic Symptoms: Mon, Tues, Wed, tHurs, Fri<ul><li>Mydriasis</li><li>Tachycardia</li><li>Weakness</li><li>Hypertension</li><li>Fasciculations</li></ul></li><li>Delayed (24h - 2 weeks) and later-onset: nicotinic, muscarinic actions and stronger CNS impairment (encephalopathy, extrapyramidal symptoms, coma).</li><li>Atropine has an issue, it only has antimuscarininc effects.</li><li>ANTIDOTE to AChEi INTOXICATION (OP): Oxime agents</li><li>Pralidoxime:<ul><li>Cholinesterase regenerator if given before aging occurs (48-hours).</li><li>Works at NMJ but does not prevent CNS effects.</li></ul></li></ul><h2 id="cholinolytics">Cholinolytics</h2><h3 id="indirect">Indirect</h3><ul><li>Botulinum Toxin:<ul><li>Cleave protein associated with fusion and exocytosis of vesicles carrying ACh (<strong>SNARE proteins</strong>)</li><li>Prevent docking and release of ACh</li><li>TI: Prevent sustained involuntary muscle spasms</li><li>Bleopharospasm (excessive blinking)</li><li>Severe axillary hyperhidrosis (excessive sweating)</li></ul></li></ul><h3 id="direct">Direct</h3><h4 id="muscarinic-anatgonists">Muscarinic Anatgonists:</h4><ul><li>Tropicamide: Causes <strong>mydriasis and cycloplegia</strong> good for use in eyes because short acting.</li><li>Tiotropium, Ipratropium: <strong>Inhaled</strong>, does not cross BBB. Mostly M3, bronchodilation, - <strong>Asthma and COPD</strong></li><li>Atropine: <strong>Reverse bradycardia</strong>, cholinergic poisoning, hyperhidrosis <strong>Dose Dependent</strong>, can also be used in the eyes</li><li>Atropine, Scopolamine: Inhibit <strong>excessive salivation and mucus secretion during surgery</strong></li><li>Scopolamine: motion sickness</li><li>Solifenacin, Tolterodine, Oxybutynin: Urinary bladder spasm/incontinence M1 and M3 affinity -&gt; <strong>OAB</strong></li><li><strong>Desloratadine and Diphenhydramine</strong> - Antihistamine drugs with additional muscarinic antagonists mech.</li><li>Antimuscarinic Syndrome:<ul><li>Red as a beet - skin flushed</li><li>Hot as a hare - Hyperthermia</li><li>Dry as a bone - Dry mucous membranes and no sweating</li><li>Blind as a bat - Blurred vision, mydriasis, cycloplegia</li><li>Mad as a hatter - Confusion</li></ul></li><li>Atropine Toxicity is dose-dependent<ul><li>++ Slight bradycardia <strong>and dry mouth</strong>/loss of sweating</li><li>+++ Dry mouth, thirst, increased heart rate, pupil dilation<h4 id="nicotinic-antagonists-nmj-blocks">Nicotinic Antagonists: NMJ blocks</h4></li></ul></li><li>Non-Depolarizing (curonium or curium) - competititve antag<ul><li>Pancuronium (long acting)</li><li>Rocuronium (intermediate)</li><li>Atracurium (intermediate)</li><li>Competitive antagonist</li><li>TI: Adjunct to general anesthesia. Facilitate intubation</li><li>AE: Hypotension, tachycardia, bronchospasms, respiratory paralysis, aspiration of gastrict contents</li><li><strong>Antidote: Effects reveresed by AChEi (neostigmine)</strong></li></ul></li><li>Depolarizing:<ul><li><strong>Succinylcholine</strong> hydrolyzed by AChE and BuChE<ul><li>Persistent stimulation of nicotinic receptor at NMJ that leads to desensitization to ACh</li><li>TI: Induce muscle relaxation</li><li>AE: Muscle weakness, post-op myalgia, Hyperkalemia (<strong>life-threatening arrhythmias/cardiac arrest</strong> esp in pediatrics), malignant hyperthermia</li><li><strong>NOT REVERSIBLE BY AChEi</strong></li><li>Antidone is Sugammadex</li></ul></li></ul></li></ul><h2 id="textbook-notes">Textbook Notes</h2><ol><li>Explain the difference between anticholinergic and antimuscarinic drugs.</li><li>Describe the mechanism of action and primary clinical use of Carbachol, Pilocarpine,Carbachol, Bethanechol, Methacholine, Varenicline, and Cevimeline.</li><li>List the symptoms of nicotine poisoning and explain why nicotine may have cholinomimetic and cholinolytic effects.</li><li>List the main differences between the AChE inhibitors (AChEi) Neostigmine and Organophosphates (e.g., parathion).</li><li>Explain why the oximes are not always as effective as AChEi antidote.</li><li>List the primary clinical use of Pyridostigmine, Neostigmine, Donepezil, Rivastigmine, and Galantamine.</li><li>Explain the mechanisms triggered for the occurrence of “DUMBEELSS”.</li><li>List the main similarities and differences among Atropine, Scopolamine, Tiotropium, Tolterodine, Solifenacin, Desloratadine, Diphenhydramine.</li><li>List and explain the (“Antimuscarinic Syndrome”) poisoning signs/symptoms.</li><li>Explain the main differences between succinylcholine and ‘curoniums’.</li></ol><ul><li>Muscarine mimicked parasympathetic nerve dischage. Its effects were <strong>parasympathomimetic</strong></li><li>. The effects of acetylcholine itself and of other cholinomimetic drugs at autonomic neuroeffector junctions are called parasympathomimetic effects and are mediated by muscarinic receptors.</li><li>nicotine stimulated autonomic ganglia and skeletal muscle neuromuscular junctions but not autonomic effector cells. The <strong>ganglion and skeletal muscle receptors were therefore labeled nicotinic</strong>.</li><li>acetylcholine was later identified as the physiologic transmitter at both muscarinic and nicotinic receptors, both receptors were recognized as <strong>cholinoceptor subtypes.</strong></li><li>Direct-acting cholinomimetic agents bind to and activate muscarinic or nicotinic receptors</li><li>Indirect-acting agents produce their primary effects by inhibiting acetylcholinesterase.<ul><li>By inhibiting acetylcholinesterase, the indirect-acting drugs increase the endogenous acetylcholine concentration in synaptic clefts and neuroeffector junctions.</li></ul></li><li>First, <em>acetylcholine released from parasympathetic nerves</em> <strong>activates</strong> muscarinic receptors on <strong>effector cells</strong> to alter organ function directly.</li><li>Second, <em>acetylcholine released from parasympathetic nerves</em> interacts with muscarinic receptors on <strong>nerve terminals</strong> to <strong>inhibit the release of their neurotransmitter</strong>.</li><li>Muscarinic agonist binding to <strong>M1, M3, and M5</strong> receptors activates the <strong>inositol trisphosphate (IP3), diacylglycerol (DAG)</strong> cascade.</li><li>Activation of <strong>M2 and M4</strong> muscarinic receptors <strong>inhibits adenylyl cyclase activity</strong> in tissues (eg, heart, intestine)</li><li>Continued presence of the nicotinic agonist <strong>prevents electrical recovery</strong> of the postjunctional membrane. Thus, a state of <strong>“depolarizing blockade”</strong> occurs initially during persistent agonist occupancy of the receptor. Continued agonist occupancy is associated with return of membrane voltage to the resting level. The receptor becomes <strong>desensitized</strong> to agonist, and this state is refractory to reversal by other agonists.</li><li><strong>Effects of direct-acting cholinoceptor stimulant</strong><ul><li>Sinoatrial node: <strong>Decrease in rate (negative chronotropy)</strong></li><li>Atria: <strong>Decrease in contractile strength (negative inotropy)</strong>. Decrease in refractory period</li><li>Atrioventricular node: <strong>Decrease in conduction velocity (negative dromotropy)</strong>. Increase in refractory period</li><li>Ventricles: Small decrease in contractile strength</li></ul></li></ul></div><footer class="wrapper post__footer"><p class="post__last-updated">This article was updated on December 6, 2020</p></footer></article><nav class="post__nav"><div class="post__nav-inner"><div class="post__nav-prev"><svg width="1.041em" height="0.416em" aria-hidden="true"><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#arrow-prev"/></svg> <a href="https://BGASM.github.io/medNotes/chemotherapy-ii.html" class="invert post__nav-link" rel="prev"><span>Previous</span> Chemotherapy II</a></div><div class="post__nav-next"><a href="https://BGASM.github.io/medNotes/virology-i.html" class="invert post__nav-link" rel="next"><span>Next</span> Virology I </a><svg width="1.041em" height="0.416em" aria-hidden="true"><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#arrow-next"/></svg></div></div></nav></main><footer class="footer"><div class="footer__copyright"><p>Powered by <a href="https://getpublii.com" target="_blank" rel="nofollow noopener">Publii</a></p></div><button class="footer__bttop js-footer__bttop" aria-label="Back to top"><svg><title>Back to top</title><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#toparrow"/></svg></button></footer></div><script>window.publiiThemeMenuConfig = {    
        mobileMenuMode: 'overlay',
        animationSpeed: 300,
        submenuWidth: 'auto',
        doubleClickTime: 500,
        mobileMenuExpandableSubmenus: true, 
        relatedContainerForOverlayMenuSelector: '.top',
   };</script><script defer="defer" src="https://BGASM.github.io/medNotes/assets/js/scripts.min.js?v=f4c4d35432d0e17d212f2fae4e0f8247"></script><script>var images = document.querySelectorAll('img[loading]');

        for (var i = 0; i < images.length; i++) {
            if (images[i].complete) {
                images[i].classList.add('is-loaded');
            } else {
                images[i].addEventListener('load', function () {
                    this.classList.add('is-loaded');
                }, false);
            }
        }</script></body></html>